Evidence map›Paper›PMID 41324413›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

Nicotinamide Attenuates Complement and Coagulation Pathways and Resultant Renal Fibrosis.

Saori Kin, Yuji Oe, Taku Obara, Emiko Sato, Nobuyuki Takahashi, Mariko Miyazaki, Tetsuhiro Tanaka

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Disulfiram Attenuates Adenine-Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Review
  3. Nicotinamide Attenuates Complement and Coagulation Pathways and Resultant Renal Fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saori KinDepartment of Nephrology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Yuji OeDepartment of Nephrology, Graduate School of Medicine, Tohoku University, Sendai, Japan.ORCID https://orcid.org/0000-0001-8558-8832
Taku ObaraDivision of Preventive Medicine and Epidemiology, Tohoku University Tohoku Medical Megabank Organization, Sendai, Japan.
Emiko SatoDivision of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Nobuyuki TakahashiDivision of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Mariko MiyazakiDepartment of Nephrology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Tetsuhiro TanakaDepartment of Nephrology, Graduate School of Medicine, Tohoku University, Sendai, Japan.

Funding

Gonryo Medical FoundationJapan Society for the Promotion of Science (JSPS) 21K16156
6 · The paper itself

Abstract

The coagulation and complement pathways interact with each other, promoting inflammation and increasing thrombotic risk. However, their roles in chronic kidney disease (CKD) remain unclear. In our CKD cohort, elevated plasma fibrinogen and shortened prothrombin time were associated with higher serum complement C3 and C4 levels. Moreover, gene expression analysis of CKD renal tissues in public databases showed a positive correlation between fibrinogen β chain and C3 expression levels. Finally, tissue factor (factor III), fibrinogen, and C3 deposition and the genes related to coagulation and complement cascades were upregulated in fibrotic kidneys of mice treated with adenine or folic acid. To explore the modulators of these systems, the therapeutic effects of nicotinamide (NAM), a NAD

Indexed as

Blood CoagulationComplement System ProteinsKidneyNiacinamideRenal Insufficiency, ChronicAnimalsFemaleFibrosisHumansMaleMiceMice, Inbred C57BLComplement System ProteinsNiacinamideinflammasomeNAD+neutrophil extracellular trapthrombosis

Identifiers

PMID41324413
PMCPMC12668026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.